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Trisomy 21 (T21) causes Down syndrome (DS), a condition charac-
terized by high prevalence of autoimmune disorders. However,
the molecular and cellular mechanisms driving this phenotype re-
main unclear. Building upon our previous finding that T cells from
people with DS show increased expression of interferon (IFN)-
stimulated genes, we have completed a comprehensive character-
ization of the peripheral T cell compartment in adults with DS with
and without autoimmune conditions. CD8+ T cells from adults
with DS are depleted of naïve subsets and enriched for differen-
tiated subsets, express higher levels of markers of activation and
senescence (e.g., IFN-γ, Granzyme B, PD-1, KLRG1), and overpro-
duce cytokines tied to autoimmunity (e.g., TNF-α). Conventional
CD4+ T cells display increased differentiation, polarization toward
the Th1 and Th1/17 states, and overproduction of the autoimmunity-
related cytokines IL-17A and IL-22. Plasma cytokine analysis confirms
elevation of multiple autoimmunity-related cytokines (e.g., TNF-α,
IL17A–D, IL-22) in people with DS, independent of diagnosis of
autoimmunity. Although Tregs are more abundant in DS, functional
assays show that CD8+ and CD4+ effector T cells with T21 are re-
sistant to Treg-mediated suppression, regardless of Treg karyotype.
Transcriptome analysis of white blood cells and T cells reveals strong
signatures of T cell differentiation and activation that correlate pos-
itively with IFN hyperactivity. Finally, mass cytometry analysis of 8
IFN-inducible phosphoepitopes demonstrates that T cell subsets with
T21 show elevated levels of basal IFN signaling and hypersensitivity
to IFN-α stimulation. Therefore, these results point to T cell dysregu-
lation associated with IFN hyperactivity as a contributor to autoimmu-
nity in DS.
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Down syndrome (DS) is caused by trisomy 21 (T21), the mostcommon chromosomal abnormality in the human pop-
ulation, affecting ∼1 in 700 newborns (1). Besides developmental
delays and highly variable cognitive deficits, T21 causes an al-
tered disease spectrum, wherein people with DS are protected
from certain diseases, such as most solid malignancies (2), but
highly predisposed to others, such as Alzheimer’s disease (AD)
(3). Remarkably, people with T21 are highly predisposed to
develop a specific spectrum of autoimmune conditions, including
autoimmune thyroid disease, celiac disease, type I diabetes, and
a range of autoimmune and autoinflammatory skin conditions
(4–6). With the exception of AD, the high prevalence of which is
due to the presence of the amyloid precursor protein gene (APP)
on chromosome 21 (chr21), the molecular and cellular bases of
this different disease spectrum are unclear.
Several genes involved in immune control are encoded on
chr21, including 4 of the 6 interferon (IFN) receptor subunits
(IFNRs): the 2 type I IFNRs (IFNAR1, IFNAR2), one type II
IFNR (IFNGR2), and IL10RB, which encodes a subunit of the
receptors for type III IFN ligands, IL-10, IL-22, and IL-26 (7).
The role of IFN signaling in development of autoimmunity is
well documented, with many genome-wide association studies
revealing strong genetic associations between polymorphisms in
components of the IFN pathway and autoimmune disorders
(reviewed in ref. 8). Recently, transcriptome analysis of 4 differ-
ent cell types from people with and without DS, including T cells,
demonstrated that T21 causes a consistent activation of the IFN
transcriptional response (9). Additionally, plasma proteomics
analyses demonstrated that people with DS have signs of chronic
autoinflammation, including elevated levels of proinflammatory
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cytokines, such as IL-6, TNF-α, MCP-1, and IL-22 (10). Thus, it is
clear that people with DS display signs of chronic inflammation,
even in the absence of diagnosed autoimmune disorders.
Less is known about alterations in cellular immunity that could
contribute to the high prevalence of autoimmune disorders and
the chronic inflammatory state in DS. Histopathologic studies of
thymic tissue from people with DS showed hypoplasia and
compromised architecture, even in newborns (11, 12), which
could explain the lower thymic output of mature αβ+ thymocytes
observed in DS (13). This decreased thymic output is consistent
with decreased naïve T cell percentages; however, so is the
reported increase in central memory and terminally differenti-
ated T lymphocytes (13–17). Although it has been shown that
individuals with T21 exhibit increased CD8/CD4 ratios and
higher frequencies of regulatory CD4+ T cells (Tregs) in pe-
ripheral blood (17–20), characterization of CD8+ and CD4+
T cell subsets has been limited to the expression of a few phe-
notypic markers in the pediatric population (14, 17, 19, 21).
In this study, we used multiparametric, high-dimensional flow
cytometry to comprehensively characterize the peripheral T cell
compartment of individuals with DS by measuring the expression
of a large panel of phenotypic markers. We also performed functional
assays, cytokine measurements, and transcriptome analyses. We
found that CD8+ T cells from individuals with T21 express markers
of activated and senescent states and respond to stimulation more
potently than their euploid counterparts, overproducing autoimmunity-
related cytokines. Conventional CD4+ T cells (Tconvs) show a polar-
ized state toward increased production of IL-17A, and plasma levels of
IL-17A, IL-17B, IL-17C, and IL-17D are elevated in DS. Interestingly,
we found that Tregs from individuals with T21 show neither significant
phenotypic differences nor impaired functional capacity relative to
control Tregs. Indeed, our results from allogeneic “criss-cross” experi-
ments indicate that the functional deficiency previously reported for
Tregs with T21 is not cell-autonomous (18). Instead, we find that T21
CD8+ T and CD4+ Tconv cells are resistant to Treg-mediated sup-
pression, regardless of Treg karyotype. Transcriptome analysis of bulk
white blood cells (WBCs) and T cells revealed gene expression signa-
tures indicative of T cell differentiation and activation which corre-
lated positively with IFN activity. Finally, mass cytometry experiments
revealed that T cells of people with DS display both elevated basal IFN
signaling and hyperactivation upon IFN-α stimulation. Altogether,
these results reveal that multiple alterations observed in the T cell
compartment of adults with T21 mimic those observed in autoimmune
conditions, even in the absence of clinical manifestation of autoim-
munity, concurrent with IFN hyperactivity.
Results
Trisomy 21 Reshapes the Peripheral T Cell Compartment away from
the Naïve State. In order to investigate the impact of T21 on the
peripheral T cell compartment, we used flow cytometry to define
alterations in the numbers and/or frequencies of different func-
tional subsets of T cells present in blood from adult individuals,
including total T cells (CD3+), CD8+, CD4+ Tconvs, and Tregs,
as well as a plethora of phenotypic markers (Dataset S1) (22).
First, we analyzed the numbers and frequencies of major T cell
subtypes in adults with T21 and age- and sex-matched euploid
controls (D21). We recruited adults to avoid observations that
could be affected by differences in early immune development.
Our research participants presented a range of comorbidities
more common in DS (6), but none of them presented signs of
infection in the weeks prior to blood draw, and all tested negative
for cytomegalovirus (CMV) infection (Dataset S2).
Although T21 does not significantly impact the frequency of
CD3+ T cells among all viable peripheral blood mononuclear
cells (PBMCs) or the total number of T cells, individuals with
T21 have a higher percentage of CD8+ T cells and a decreased
frequency of CD4+ T cells within the CD3+ population, leading
to an increased CD8/CD4 ratio (Fig. 1A and SI Appendix, Fig. S1
A–C). When we classified CD4+ T cells into Tconvs and Tregs,
we observed a decrease in the percentage of Tconvs and an in-
crease in the percentage of Tregs (Fig. 1B and SI Appendix, Fig.
S1A). Then, we evaluated the number of cells per milliliter, which
revealed that people with DS have a higher number of CD8+ T
and Tregs (Fig. 1C), with no significant differences in the number
of total CD4+ T and CD4+ Tconvs (SI Appendix, Fig. S1D). We
also observed a positive correlation between the numbers of
CD8+ T cells and Tregs in both groups (SI Appendix, Fig. S1E).
Interestingly, concurrent increases in CD8+ T cells and Tregs
have been observed in autoinflammatory conditions (23, 24).
T cells are classified as naïve or memory, depending on their
location, functional status, cytokine expression, and their history
of antigen-induced activation. To obtain an overview of the
T cell subsets in people with DS, we reduced the flow cytometry
data to 2 dimensions by applying the t-distributed stochastic
neighbor embedding (t-SNE) algorithm, where we considered
the differential expression of 12 parameters, including surface
markers, transcription factors, and signaling and activation
molecules (SI Appendix, Fig. S2 A and B). These analyses were
performed in conjunction with Flow Self-Organizing Maps
(FlowSOM) clustering (25), which resolved 9 T cell subpopula-
tions: potentially naïve (PNa, CD45RA+ CCR7+ cells, which
include true naïve and stem cell memory-like T cells or TSCMs),
central memory (TCM), effector memory (TEM), and termi-
nally differentiated effector (TEMRA) CD8+ T cells; PNa
and memory CD4+ Tconvs; Tregs; double-positive CD4+/CD8+
T cells; and non-CD4+/CD8+ T cells (Fig. 1D and SI Appendix,
Fig. S2B). The most prominent change among CD3+ T cells in
people with T21 was a reduction in the proportion of PNa cells
among CD8+ and CD4+ T cells, concurrent with an increase in
the frequency of TEMRA CD8+ T cells (Fig. 1E). We next
analyzed the CD8+ and CD4+ T cell subsets in greater detail by
manual gating using surface markers to discriminate the fol-
lowing 5 subpopulations (SI Appendix, Fig. S2C): truly naïve,
TSCM, TCM, TEM, and TEMRA (26). This exercise confirmed
that, among total CD8+ T cells, people with DS have lower
levels of naïve CD8+ T cells and higher levels of TEM and
TEMRA populations (Fig. 1F). When analyzed in terms of fre-
quency among all CD8+ T cells, TSCMs were not found to be
different; however, when calculated as a fraction of all
CD45RA+ CCR7+ cells [commonly identified as naïve T cells in
the literature (27)], there is an increase in TSCMs in people with
DS (Fig. 1F). This discrepancy can be explained by the fact that
the increase in TSCMs occurs in the background of decreased
CD45RA+ CCR7+ cells (SI Appendix, Fig. S2D). Among CD4+
T cells, there was a similar depletion of naïve cells and an
increase in the TCM population along with an increase in
TSCMs among PNa CD4+ T cells (Fig. 1G). Next, we in-
vestigated alterations in Tregs by measuring expression of
FOXP3, a key transcription factor in their development and
function (28, 29). Since FOXP3+ T cells may not be function-
ally homogeneous, due to the transient expression of FOXP3
during activation of Tconvs, we used the expression of CD45RA
and FOXP3 to distinguish 3 phenotypically distinct subpopula-
tions (30): FOXP3+ non-Tregs (CD45RA-/FOXP3low), PNa
Tregs (CD45RA+/FOXP3low), and effector Tregs (CD45RA-/
FOXP3high) (SI Appendix, Fig. S2E). Although there is no re-
distribution among the PNa and effector Tregs, effector Tregs
express more FOXP3 in people with DS (SI Appendix, Fig. S2F). As
expected, effector Tregs express the most FOXP3 relative to the
other populations (SI Appendix, Fig. S2F), showing the classical
CD25high CD127low phenotype and producing the lowest levels
of IFN-γ (SI Appendix, Fig. S2G).
Altogether, these results indicate that T21 disrupts peripheral
T cell homeostasis, affecting the frequencies and total numbers
of key T cell subtypes, thus justifying a deeper characterization of
these populations.






















Trisomy 21 Drives CD8+ T Cell Differentiation toward a Hyperactivated
State.Having observed an increase in both frequency and number of
total CD8+ T cells in people with DS, along with a redistribution
away from the naïve state, we investigated the expression of markers
of activation, proliferation, and senescence in this T cell subset (31).
First, we evaluated the levels of granzyme B (GZMB), IFN-γ, and
TNF-α after stimulating CD8+ T cells with phorbol 12-myristate 13-
acetate (PMA)/Ionomycin and found that all 3 effector markers
were elevated in cells from people with T21 compared to D21 (Fig.
2A). We also found increased frequency of CD8+ T cells that si-
multaneously produced 2 of these effectors, GZMB/IFN-γ or IFN-
γ/TNF-α (SI Appendix, Fig. S3A), illustrating the polyfunctionality
of these cells. CD8+ T cells from people with DS also expressed
more Ki-67, consistent with increased cell proliferation upon acti-
vation (Fig. 2B). We also found increased levels of effector molecules
and Ki-67 in some of the phenotypically matched subsets defined by
CD45RA and CCR7 marker expression (PNa, TCM, TEM, and
TEMRA) (Fig. 2C and SI Appendix, Fig. S3B). Whereas the increases
in the CD45RA+ CCR7+ subset could be attributed, in part, to the
increased fraction in TSCMs, even TEMRAs showed increases in
GZMB, IFN-γ, and Ki-67 (Fig. 2C and SI Appendix, Fig. S3C).
Next, we examined cytokines produced by CD8+ T cells in
vitro upon stimulation with anti-CD3/CD28. Remarkably, 28 of
the 29 cytokines detected were more abundant in the superna-
tant of T21 CD8+ T cells, 10 of them significantly (Fig. 2D, SI
Appendix, Fig. S3D, and Dataset S3). We observed elevated
levels of cytokines known to be produced by CD8+ T cells, in-
cluding TNF-α, IFN-γ, IL-2, and MIP-1α (32–35). Notably,
overproduction of GM-CSF by CD8+ T cells has been observed
in autoimmune conditions (36), and overproduction of antiin-
flammatory IL-10 is indicative of negative feedback within this
subset (37). Others and we have observed elevation of many of
the cytokines overproduced by CD8+ T cells in the plasma of
people with DS, including TNF-α, IL-2, MIP-1α, IL-10, Eotaxin,
and IL-8 (SI Appendix, Fig. S3E) (10, 38). However, extended
analysis of cytokine profiles of people with DS revealed no dif-
ferences between those with diagnoses of autoimmune condi-
tions and those without (Dataset S2 and SI Appendix, Fig. S3F).
Lastly, we measured the expression of the transcription factors
T-bet (T-box 21, TBX21) and Eomesodermin (EOMES), which
play well-recognized roles in CD8+ T cell differentiation, senes-
cence, and exhaustion (39). In CD8+ T cells, T-bet is up-regulated
upon activation and is associated with induction of effector func-
tions, including cytotoxicity, whereas EOMES expression is higher in
long-term, stable, self-renewing memory CD8+ T cells, and has also
been associated with a dysfunctional phenotype (39). We observed
that the frequency of T-bet+ EOMES+ CD8+ T cells is increased in
people with DS (Fig. 2E). We also examined how the expression of
T-bet and EOMES associated with effector markers of CD8+ T cell
function and found an increase in IFN-γ+ TNF-α+ T-bet+ EOMES+
CD8+ T cells in people with DS (Fig. 2F). Moreover, the T-bet/
EOMES ratio is higher in DS, consistent with an enhanced effector
phenotype (Fig. 2G).
In sum, these findings indicate that CD8+ T cells from people
with DS have a markedly altered program of differentiation to-
ward hyperactivation, cytokine overproduction, and increased
functionality.
CD8+ T Cells from People with DS Show Signs of Increased
Senescence. The fact that people with DS showed an increase
in differentiated CD8+ T cell subsets prompted us to determine
whether these cells had acquired a senescent phenotype, as is
observed in chronic inflammatory settings (40). To test this, we
measured expression of the inhibitory receptors PD-1, TIGIT,
and BTLA, and the senescence markers CD57 and KLRG1.
Samples with T21 showed an increased frequency of CD8+
T cells expressing PD-1 and TIGIT (Fig. 3A), but not BTLA (SI
Appendix, Fig. S4A), which is expressed by most naïve CD8+
T cells (41). Next, we investigated coexpression of these recep-
tors and found a greater proportion of CD8+ T cells coex-
pressing all 3 inhibitory receptors in T21 samples (Fig. 3B).
Individuals with DS also have a higher percentage of CD8+
T cells positive for CD57 and KLRG1 (Fig. 3C), as well as higher
numbers of cells expressing both markers (Fig. 3D). Of note is
that individuals with T21 also exhibit a higher frequency of
KLRG1+ CD57− CD8+ T cells, again indicative of an activated
state (42) (Fig. 3D). Importantly, many of these increases in
senescence markers were also observed when comparing phe-
notypically matched subsets of CD8+ T cells (Fig. 3E and SI















































































































































































































Fig. 1. Adults with trisomy 21 show dysregulated T cell homeostasis. (A) Frequencies of CD8+ and CD4+ T cells within the CD3+ T cells in euploid controls
(D21) versus people with trisomy 21 (T21) (n = 14 D21; n = 9 T21). (B) Percentage of CD4+ Tconv (CD4+ CD25low CD127high) and CD4+ Treg (CD4+ CD25high
CD127low FOXP3+) cells among CD4+ T cells. (C) Numbers of CD8+ and CD4+ Treg cells in peripheral blood in people with and without T21. (D) A t-SNE map
showing a random subsample of circulating T cells from individuals with and without T21, analyzed with FlowSOM clustering. (E) Frequencies of CD8+ PNa,
CD8+ TEMRA, and CD4+ PNa Tconv cells within the CD3+ T cells obtained by FlowSOM clustering. (F and G) (Left) Frequencies of (F) CD8+ and (G) CD4+ T cells
subsets based on expression of CCR7, CD45RA, CD45RO, CD27, and CD95 as shown in SI Appendix, Fig. S2C. (Right) Proportion of TSCMs among potentially
naïve CD8+ and CD4+ T cells (n = 12 D21; n = 10 T21). Data in A–C, E, F, Right, and G, Right are shown as mean ± SEM with significance determined by
unpaired t test; data in Left F and G are shown as mean ± SEM with significance determined by 2-way ANOVA with Sidak’s posttest. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001.










































In the CD8+ T cell response, the effector state precedes the
memory state and may divert to a senescent phenotype upon
chronic stimulation. Accordingly, cells can exist in an intermediate
state where they express both activation and inhibitory/senescent
markers. When we measured coexpression of these markers, sam-
ples with T21 showed an elevated frequency of cells that coexpress
IFN-γ or TNF-α with PD-1, KLRG1, and CD57 (Fig. 3F and SI
Appendix, Fig. S4D). Finally, we measured the expression of T-bet
and EOMES in CD57+ and KLRG1+ CD8+ T cells, which
revealed that adults with DS exhibit increased T-bet (but not
EOMES) in KLRG1+ CD57+ and KLRG1+ CD57−CD8+ T cells
(SI Appendix, Fig. S4E). This intermediate phenotype has been
associated with senescence of CD8+ T cells in aged individuals (43).
Overall, these findings indicate that CD8+ T cells from people
with DS show signs of differentiation toward activated and se-
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Fig. 2. CD8+ T cells from adults with trisomy 21 show signs of hyperactivation. Fresh PBMCs from individuals with and without DS were stimulated ex vivo
with PMA/Ionomycin before flow cytometry analysis. (A) (Top) Representative histograms showing the expression levels (mean fluorescence intensity [MFI]) of
GZMB, IFN-γ, and TNF-α on total CD8+ T cells from individuals with T21 (blue) and typical controls (D21, black) compared to fluorescence minus one (FMO) on
CD8+ T cells (white). (Bottom) Scatter plots display frequencies of GZMB (n = 14 D21; n = 9 T21), IFN-γ, and TNF-α (n = 19 D21; n = 12 T21) positive events
among CD8+ T cells. (B) (Left) Representative histogram and (Right) frequencies of Ki-67 expression among CD8+ T cells (n = 14 D21; n = 9 T21). (C) Heatmap
showing the frequencies of GZMB, IFN-γ, and TNF-α positive events within the CD8+ T cell subsets, as defined in SI Appendix, Fig. S2C, in individuals with and
without T21. (D) Volcano plot showing fold changes (log2 T21 over D21) and P values (log10) for cytokine levels produced by CD8+ T cells after being
stimulated with anti-CD3/CD28, detected by MSD. Vertical dashed line represents the no-change midline. Horizontal dashed line represents P value of 0.05 as
calculated by Student t test. (E) Scatter plot showing the coexpression of T-bet and EOMES among total CD8+ T cells (n = 19 D21; n = 12 T21). (F) (Left) Pie
charts illustrating the expression pattern of IFN-γ, TNF-α, T-bet, and EOMES within the CD8+ T cell population. Pie-section colors correspond to the number of
markers expressed on a cell. Arcs around the pie represent which marker(s) are expressed. (Right) Coexpression of IFN-γ, TNF-α, T-bet, and EOMES among
CD8+ T cells. (G) Ratio of T-bet+ to EOMES+ among CD8+ T cells in people with and without T21 (n = 19 D21; n = 12 T21). Data in A–G are shown as mean ±
SEM with significance determined by unpaired t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.






















capable of proliferating and producing effector cytokines to a
greater extent than their euploid counterparts.
Conventional T Cells from People with Trisomy 21 Are Polarized
toward the Th1 and Th1/17 States. Given our findings that indi-
viduals with T21 show anomalies in the distribution of naïve/
memory CD4+ T cells (Fig. 1G), we next investigated their po-
larization into biologically distinct subsets by evaluating the ex-
pression of chemokine receptors (SI Appendix, Fig. S5A).
Th1 and Th1/17 subsets were enriched among CD4+ Tconvs
from people with T21, with no differences in Th17, Th2, and Tfh
subsets (Fig. 4A). Evaluation of cytokines produced by CD4+
Tconvs stimulated in vitro with anti-CD3/CD28 revealed ele-
vated levels of IL-10, IL-17A, IL-22, and MIP-3α in T21 samples
(Fig. 4B, SI Appendix, Fig. S5B, and Dataset S3). Other IL-17
isoforms were below detection limits in these assays (Dataset
S3). The increased levels of IL-10 are consistent with self-
regulation within this subset (44), and the elevated levels of IL-
17A and IL-22 are consistent with the observed increase in the
Th1/17 subset (45, 46). The increase in MIP-3α (CCL20, the li-
gand for CCR6) is indicative of increased CCR6-dependent
signaling, a hallmark of the Th1/17 and Th17 subsets (45, 47).
Differences in Th1 cytokines, such as TNF-α and IFN-γ, did not
reach statistical significance (Fig. 4B). Of note is that the Tfh
cytokine IL-21 was not detected in these assays (Dataset S3). We
next investigated plasma levels of several IL-17 isoforms, IL-22,
MIP-3α, and IL-21, which revealed increases in IL-17A, IL-17B,
IL-17C, IL-17D, IL-22, and MIP-3α, but not in IL-17E, IL-17F,
and IL-21 in people with DS (Fig. 4C and Dataset S3). We found
no differences in IL-17 isoforms or IL-22 between people with
DS with or without a confirmed diagnosis of an autoimmune
condition (SI Appendix, Fig. S5C). Thus, dysregulation of the
CD4+ compartment could also contribute to the autoimmunity-
related cytokine profile of DS.
Effector T Cells with Trisomy 21 Are Resistant to Treg-Mediated
Suppression. The enhanced activation phenotype observed in
CD8+ and CD4+ T cells of people with DS, which is accom-
panied by increased numbers of FOXP3+ Tregs (Fig. 1C),
prompted us to test for differences in Treg functionality. We
analyzed 14 phenotypic markers to study the proliferation, acti-
vation, inhibitory potential, functional specialization, and ef-
fector properties of Tregs, which revealed minor effects of
karyotype (SI Appendix, Fig. S5 D and E). PNa Tregs expressed
more of both Ki-67 and the activation marker Helios, but less
PD-1 (SI Appendix, Fig. S5 D and E). In contrast, effector Tregs,
which express more FOXP3 in people with DS (SI Appendix, Fig.
S2F), also express more of the costimulatory molecule GITR (SI
Appendix, Fig. S5 D and E).
To further test Treg functionality, we performed allogeneic
“criss-cross” suppression assays (24, 48–50), in which Tregs from
people with and without DS were isolated and titrated into re-
sponder cells with or without T21. In this way, we could in-
dependently define the impact of karyotype on responder cells
(either CD8+ T or CD4+ Tconv cells) versus impacts on Treg









































































































































































































































































Fig. 3. CD8+ T cells from adults with trisomy 21 show increased expression of inhibitory receptors and senescence markers. Fresh PBMCs from individuals
with and without DS were stimulated ex vivo with PMA/Ionomycin before flow cytometry analysis. (A) (Top) Representative histograms showing the ex-
pression levels (MFI) of PD-1 and TIGIT on total CD8+ T cells from individuals with T21 (blue) and typical controls (D21, black) compared to FMO on CD8+ T cells
(white). (Bottom) Display frequencies of PD-1 and TIGIT positive events among CD8+ T cells (n = 19 D21; n = 12 T21). (B) (Top) Pie charts illustrating the mean
percentage of inhibitory receptor coexpression on total CD8+ T cells from people with and without T21 (n = 19 D21; n = 12 T21). Pie chart colors correspond to
the number of inhibitory receptors expressed on a cell. Arcs around the pie represent which inhibitory receptor(s) are expressed. (Bottom) Coexpression of PD-1,
TIGIT, and BTLA among CD8+ T cells. (C) Representative (Top) histograms and (Bottom) frequencies of CD57 and KLRG1 expression among CD8+ T cells (n =
19 D21; n = 12 T21). (D) Representative (Top) flow cytometric data and (Bottom) frequencies for coexpression of the senescence markers KLRG1 and
CD57 among CD8+ T cells. (E) Heatmap showing the frequencies of PD-1, TIGIT, KLRG1, CD57, and PD1/KLRG1/CD57 positive events within the different
subsets of CD8+ T cells, as defined in SI Appendix, Fig. S2C, in individuals with and without T21. (F) (Left) Pie charts as in B showing the coexpression pattern of
the effector molecule IFN-γ and the indicated inhibitory receptors and senescence markers on the CD8+ T cell population (n = 19 D21; n = 12 T21). (Right)
Coexpression of IFN-γwith PD-1, KLRG1, and CD57 among CD8+ T cells. Data in A–F are shown as mean ± SEM with significance determined by unpaired t test.
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.










































showed a similar ability to suppress responder CD8+ T and CD4+
Tconv cells from D21 individuals (Fig. 5A and SI Appendix, Fig.
S6A). In contrast, both CD8+ T and CD4+ Tconv cells with
T21 were more resistant to Treg-mediated suppression, regardless
of the Treg karyotype (Fig. 5 B and C and SI Appendix, Fig. S6 B
and C). Further analysis of effector cells upon stimulation with anti-
CD3/CD28 in the absence of Tregs revealed that T21 CD8+ T cells
display a higher rate of proliferation (Fig. 5D), an increased ex-
pression of the activation marker CD25 (IL-2 receptor alpha) (Fig.
5E), and increased expression of the effector molecules GZMB,
IFN-γ, and TNF-α (Fig. 5F). For CD4+ Tconvs, we observed in-
creased proliferation as well as increased expression of CD25 and
IFN-γ (SI Appendix, Fig. S6 D–F).
Altogether, these data show that effector T cells from people
with DS are less sensitive to suppression by Tregs, which could
further contribute to the inflammatory state in those with T21.
Transcriptome Analysis of Trisomy 21 Cells Reveals Signatures
Indicative of T Cell Activation and Differentiation Associated with
IFN Hyperactivity. In order to gain mechanistic insights into the
signaling pathways dysregulated by T21 that could contribute to
the observed changes in the T cell compartment, we analyzed
transcriptome data from WBCs from 19 individuals, 10 of them
with T21 (Datasets S2 and S4) (51). DESeq2 analysis of differ-
entially expressed genes (DEGs) revealed that T21 causes a
distinct gene expression signature consisting of 497 down-
regulated messenger RNAs (mRNAs) and 406 up-regulated
mRNAs (false discovery rate [FDR] < 10%, SI Appendix, Fig.
S7A). Of note is that 96 of the significantly up-regulated genes,
but none of the significantly down-regulated genes, are encoded
on chr21, consistent with the expected effects of increased gene
dosage (SI Appendix, Fig. S7A). However, ∼90% of DEGs are
encoded elsewhere in the genome, indicating the existence of sig-
naling cascades dysregulated by the trisomy. In order to identify
these signaling pathways, we employed the Upstream Regulator
analysis tool of the Ingenuity Pathway Analysis (IPA) software
(52), a bioinformatics tool that uses thousands of available gene
expression datasets and myriad other experimental evidence to
predict the “upstream regulators” (i.e., driving factors) re-
sponsible for the gene expression changes observed in a given
experimental condition (52). IPA revealed that the top 2 up-
stream regulators predicted to be activated in WBCs with
T21 are CD3 and CD28, the coreceptors mediating T cell acti-
vation (Fig. 6A). Therefore, although the samples were pro-
cessed immediately after blood draw without any stimulation,
samples with T21 resemble samples known to have activated
T cells. Importantly, these predictions are identical when we
employed only DEGs not encoded on chr21, indicating that
these predictions are driven by the genome-wide signature (non-
chr21, Fig. 6A). Although variable among individuals with T21,
the CD3 scores (calculated from a gene signature composed of
38 mRNAs; Dataset S5) are ∼40-fold higher in people with DS
(Fig. 6B), indicating that, while the total number of CD3+ cells is
not elevated in DS, when looking at the entire WBC population,
the most prominent gene expression changes are consistent with
a more activated T cell compartment. Examples of genes in the
CD3 signature elevated in samples with T21 are shown in SI
Appendix, Fig. S7B. Other upstream regulators predicted to be
activated in people with DS include cytokines (IL-18, IL-1β, IL-
2) and components of the IFN signaling pathway (IRF7, TLR7,
IFN-beta, IFNG, IFN alpha) (see Fig. 6A and B for IFN alpha
scores). Although CD3 signatures and IFN alpha signatures are
clearly different (Dataset S5), there was a strong positive cor-
relation between CD3 and IFN scores in WBCs (SI Appendix,
Fig. S7C).
To further investigate this phenomenon, we employed the
same analysis on RNA sequencing (RNAseq) data previously
generated from bulk T cells (CD45+CD3+CD14−CD19−CD56−)
(9), which revealed that 5 of the top 10 upstream regulators pre-
dicted to be activated in T21 samples belong to the IFN pathway
(IFN alpha, IRF7, IRF1, IFNA2, IFNG) (Fig. 6C). Interestingly,
the top upstream regulator is CSF2/GM-CSF (Fig. 6 C and D), a
cytokine overproduced by CD8+ T cells with T21 (Fig. 2D and SI
Appendix, Fig. S3D). Once again, these signatures are driven
mostly by DEGs not encoded on chr21, and enriched for canonical
IFN-stimulated genes, leading to highly elevated IFN scores in
T cells of people with DS (Fig. 6D).
Next, we performed Gene Set Enrichment Analysis (GSEA)
to further explore to what degree the gene expression changes
observed are consistent with differences in cellular composition
and/or specific signaling events. We completed this analysis for
both WBCs and T cells, which produced very similar results
(Dataset S6). When we analyzed the T cell transcriptome data
with the GSEA Hallmark gene sets, the most prominently
enriched gene sets were IFN gamma, mTORC1, and IFN alpha
(Fig. 6E, SI Appendix, Fig. S7D, and Dataset S6). Of note is that
mTOR has been shown to be chronically activated in DS (53)
and to be required for types I and II IFN responses (54, 55).
Next, we interrogated the T cell transcriptome with the GSEA
Immunological Signatures gene sets, which revealed signs of
T cell activation and differentiation in samples with T21 (Fig. 6E




























































































































Fig. 4. Conventional CD4+ T cells from adults with trisomy 21 are polarized
toward the Th1 and Th1-like Th17 states. Fresh PBMCs from individuals with
and without DS were stained and analyzed by flow cytometry. (A) Scatter
plots showing the frequencies of cells expressing the indicated chemokine
receptor combinations among CD4+ Tconv cells (n = 12 D21; n = 10 T21). (B)
Volcano plot showing fold changes (log2 T21 over D21) and P values (log10)
for cytokines produced by CD4+ Tconv cells after being stimulated with anti-
CD3/CD28 detected by MSD. Vertical dashed line represents the no-change
midline. Horizontal dashed line represents P value of 0.05 as calculated by
Student t test. (C) Box and whisker plots showing the levels (log2 concen-
tration) of IL-17A, IL-17B, IL-17C, IL-17D, IL-22, and MIP-3α in plasma of in-
dividuals with and without T21 (n = 54 D21; n = 74 T21) measured by MSD.
Data in A are shown as mean ± SEM with significance determined by 2-way
ANOVA with Sidak’s posttest; data in B and C are shown as mean ± SEM with
significance determined by unpaired t test. *P < 0.05; **P < 0.01; ***P <
0.001; ****P < 0.0001.






















and Dataset S6). For example, among the top signatures associated
with T21 were genes elevated in PD-1 high CD8+ T cells over
naïve CD8+ T cells (e.g., T-bet/TBX21, EOMES) and genes up-
regulated during exposure of CD4+ T cells to the superantigen
toxic shock syndrome toxin (e.g., Ki-67/MKI67 and other cell
cycle genes) (Fig. 6F, SI Appendix, Fig. S7 E and F, and Dataset
S6). Of note is that these signatures are mostly nonoverlapping
(SI Appendix, Fig. S7E), indicating that different fractions of the
T21-associated signature can be attributed to shifts in the CD8+
and CD4+ subsets toward activated effector states. Lastly, the T cell
RNAseq not only confirmed transcriptional induction of T-bet/
TBX21 and EOMES in T cells of people with DS but also revealed
that expression of both factors correlated positively with the IFN
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Fig. 5. Effector T cells from people with trisomy 21 are resistant to Treg suppression. CD4+ Treg and CD8+ T cells from individuals with and without DS were
titrated in criss-cross combinations in anti-CD3/CD28-stimulated cultures, and proliferation of CD8+ T cells was subsequently measured based on CellTrace Violet (CTV)
dilution. (A and B) Representative examples comparing (A) CD4+ Treg from D21 and T21 samples titrated against the same violet-labeled D21 CD8+ T cells and (B)
same CD4+ Treg from D21 titrated against violet-labeled T21 or D21 CD8+ T cells. (C) Percentage of suppression in the criss-cross combinations cultured for 5 d in the
presence of anti-CD3/CD28 at the indicated ratios of Treg:CD8+ T cells. (D) Representative histogram showing (Left) CTV dilution and (Right) division indices of CD8+
T cells from individuals with and without DS, after 5 d of culture in presence of anti-CD3/CD28. (E and F) Representative (Top) flow cytometric analysis and (Bottom)
frequency of (E) CD25 and (F) GZMB, IFN-γ, and TNF-α among gated CD8+ T cells, after 5 d of culture in presence of anti-CD3/CD28 and stimulated for the last 4 h with
PMA/Ionomycin. Data in C are shown as mean ± SEMwith significance determined by 2-way ANOVAwith Tukey’s posttest; data inD–F are shown as mean ± SEMwith
significance determined by unpaired t test (n = 7 D21 and 7 T21). *P < 0.05; **P < 0.01; ****P < 0.0001.










































Altogether, these results indicate that the clear signs of T cell
activation and differentiation in people with DS correlate posi-
tively with increased IFN signaling.
T Cell Subsets with Trisomy 21 Are Hypersensitive to IFN Stimulation.
We next hypothesized that the IFN signature observed in T cells
of people with DS could be driven by the IFNRs encoded on
chr21, which we previously demonstrated to be overexpressed in
bulk T cells at the mRNA level (9). We also showed previously
that fibroblasts with T21 respond to lower doses of types I and II
IFN ligands relative to D21 counterparts (9). In order to in-
vestigate whether T cell subsets with T21 are also hypersensitive
to IFN stimulation, we employed mass cytometry to measure
IFN-α−inducible intracellular signaling cascades using phos-
phospecific antibodies against the transcription factors STAT1-6,
the kinases ERK1-2, and the translation factor 4E-BP1, all of
which are known targets of IFN-inducible phosphorylation. Our
antibody panel also enabled us to discriminate 9 different T cell
subsets by manual gating, including 4 subsets of CD8+ T and
CD4+ Tconv cells (PNa, TEM, TCM, and TEMRA), and Tregs
(Datasets S1B and S2 and SI Appendix, Fig. S8A) (56). First, we
monitored the effect of IFN stimulation on D21 samples, which
confirmed that most phosphoepitopes are indeed IFN-inducible
in T cell subsets (SI Appendix, Fig. S8B). Evaluation of the im-
pact of T21 on basal IFN signaling revealed that most epitopes
are elevated in T cell subsets from people with DS prior to any
IFN stimulation (Fig. 7 A and B and SI Appendix, Fig. S8C). In
CD8+ T cells, the most basally elevated epitopes were p4E-BP1
in all 4 subsets, pSTAT1 in TEMs, and pSTAT4 in PNa and TEM
subsets (Fig. 7 A, C, and D). Among CD4+ Tconvs, p4E-BP1 was
the most elevated epitope at baseline in all 4 subtypes (Fig. 7 B–
D). In Tregs, the most elevated epitope at baseline was pSTAT6
(Fig. 7D and SI Appendix, Fig. S8 C and D).
The greatest impacts of T21 were observed upon IFN-α
stimulation, with T cell subsets from people with DS showing
hyperactivation of most epitopes tested (compare x axis scales in
Basal versus +IFN-α volcano plots in Fig. 7 A and B and SI
Appendix, Fig. S8C); however, IFN-inducible phosphorylation
events were different across distinct T cell subpopulations, with
some epitopes being more abundant in some cell types than
others (Fig. 7D). To visualize this phenomenon more clearly, we
employed FlowSOM clustering to identify diverse communities
of T cells (SI Appendix, Fig. S8E) and then overlaid the in-
formation from the phosphoepitopes. This exercise revealed a
heterogenous distribution of signaling events across T cell sub-
sets, with clear differences among phosphoepitopes. For exam-
ple, while pSTAT1 has maximum signals in the CD4+ TCM
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Fig. 6. Transcriptome analysis reveals gene expression signatures indicative of T cell activation in adults with trisomy 21. RNAseq analysis was performed
using bulk WBCs (n = 9 D21; n = 10 T21). (A) Heatmap displaying the results of examining the RNAseq data using the Upstream Regulator tool of the IPA
software. Factors predicted to drive the gene expression changes observed are labeled to the left of the heatmap, with CD3 on top. From left to right, the
analysis was performed using all DEGs, DEGs not encoded on chr21 (non-chr21), and DEGs encoded on chr21. (B) Dot and whisker plots showing (Top)
CD3 activation scores and (Bottom) IFN alpha scores derived from WBC samples with and without T21. (C) Upstream regulator analysis as in A using RNAseq
data derived from bulk T cells (n = 7 D21; n = 10 T21). (D) Dot and whisker plots of (Left) CSF2 scores and (Right) IFN alpha scores derived from T cells with and
without T21. (E) Enrichment plots from GSEA of T cell RNAseq data, using (Left) the Hallmarks gene sets or (Right) Immunological Signature gene sets.
Normalized Enrichment Score (NES) and FDR-corrected q values are shown. (F) Dot and whisker plots for T-bet mRNA levels from (Left) T cell RNAseq data and
(Right) the GSE26495 dataset. Benjamini−Hochberg adjusted P values were calculated using DESeq2 and GEO2R (ebayes), respectively. (G) Pearson correlation
analysis for IFN alpha scores versus T-bet mRNA expression in T cells. Data in B, D, and F are shown as mean ± SD with significance determined by unpaired
t test; data in G are shown as correlation with significance determined by Pearson’s correlation. **P < 0.01; ***P < 0.001 ****P < 0.0001.






















Altogether, these results reveal that T cells from individuals
with T21 show higher levels of basal IFN signaling and are also
hyperresponsive to type I IFN stimulation.
Discussion
Despite substantial research efforts, the mechanisms by which
T21 causes the immune anomalies reported in people with DS
remain unclear. The situation is even more complex when in-
vestigating the adult immune system, as it becomes harder to
dissect the direct effects of the extra chromosome versus envi-
ronmental and lifestyle variables working across the lifespan of
people with DS. Most of what is known regarding the peripheral
immune system in people with DS comes from studies in chil-
dren. These reports agree on an immune profile that resembles
one of older typical people: a skewed distribution of the naïve/
effector memory subsets, an increased CD8/CD4 ratio of un-
known etiology, and a dysfunctional immune response (13, 57,
58). However, little is known about the alterations in the T cell
compartment of fully developed adults with DS. Given the re-
markable increase in life expectancy for individuals with DS (1),
and the interesting observation that they display a different
disease spectrum relative to the typical adult population (6), a
deep study of their T cell compartment is amply justified. Here,
we report that the peripheral T cell compartment of adults with
DS is highly dysregulated, with multiple events associated with
the development of autoimmunity in the typical population.
Our results demonstrate that adults with DS have a higher
number of CD8+ T cells, leading to a persistently high CD8/
CD4 ratio, which correlates positively with increased frequency
and number of CD4+ Tregs. We found that CD8+ T cells from
T21 individuals are functional and more proliferative than their
D21 counterparts after polyclonal stimulation, and overproduce
cytokines tied to autoimmunity (e.g., TNF-α). They also show
signs of polyfunctionality, defined by higher expression of several
effector molecules and more than one inhibitory receptor on
their surface. These results suggest that the CD8+ T cell com-
partment of people with DS shares features observed in auto-
immune and autoinflammatory conditions (23, 59, 60). Interestingly,
the phenotype observed in the CD8+ T cells from adults with DS
is consistent with chronic type I IFN hyperactivity, as type I IFN
signaling cannot only lead to CD8+ T cell activation but also to
expression of negative immune regulators during prolonged viral
infections, such as PD-1/PD-L1 (61). Importantly, cytokine anal-
ysis showed that inflammatory markers overproduced by CD8+
T cells with T21 are also elevated in plasma of people with DS.
Future studies will be required to define whether CD8+ T cells
with T21 are more capable of killing target cells, which could
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Fig. 7. T cells of people with trisomy 21 are hypersensitive to IFN-α stimulation. Whole blood was incubated directly ex vivo for 30 min with (+IFN-α) or
without (basal) IFNα-2A, before being processed for mass cytometry analysis of 8 different phosphoepitopes in 9 different T cell subsets (see SI Appendix, Fig.
S8A for gating strategy). (A and B) Volcano plots showing fold changes by karyotype (T21 versus D21) either (Left) under basal conditions or (Right) after
stimulation with IFNα-2A on subsets of (A) CD8+ T cells and (B) CD4+ Tconv cells. Fold change was calculated as the arcsinh ratio of samples from people with
T21 minus that of samples of typical people (D21). All data represent one Helios run containing a total of n = 8 biologically independent replicates per group.
Vertical dashed line represents the no-change midline. Horizontal dashed line represents P value of 0.05 as calculated by Student t test. (C) Dot plots dis-
playing geometric mean metal intensity (gMMI) for the indicated epitopes and cell types, with lines connecting the basal and IFN-α−stimulated values for
each sample. (D) Scatter plots showing the gMMI of pSTAT1, pSTAT4, pSTAT6, and p4E-BP1 among the indicated T cell subsets in people with and without
T21 before and after stimulation with IFNα-2A. Data in C are shown as mean ± SEM with significance determined by 2-way ANOVA with Sidak’s posttest. *P <
0.05; **P < 0.01.










































reveal why this population is protected from diverse solid
malignancies (2).
Previous efforts to characterize the polarization of CD4+
Tconvs in adults with T21 have led to contradictory conclusions
(19, 21). We show here that CD4+ Tconvs from people with DS are
polarized toward the Th1 and Th1/17 states, overproducing IL-17A
and IL-22, concurrent with higher levels of circulating IL-17A-D
and IL-22 in plasma compared to controls. The role of IL-17−
expressing cells in the pathogenesis of inflammatory and auto-
immune disease is well known, particularly in autoimmune dis-
eases characterized by high levels of type I IFN signaling, such as
in systemic lupus erythematosus (SLE) and dermatomyositis (62).
Furthermore, it has been hypothesized that type I IFN and IL-17 act
in concert to sustain and amplify autoimmune and inflammatory
responses (62), making them a dangerous combination involved in
the pathogenesis of autoimmune diseases, which could explain the
increased incidence of autoimmune conditions observed in DS.
Interestingly, the increase in IL-10 could be indicative of dampening
mechanisms preventing the widespread development of autoimmunity
in DS (44).
Our findings demonstrate that Tregs show increased numbers and
higher FOXP3 expression in people with T21, yet our analysis did not
detect major phenotypic differences. Furthermore, when allogenic
criss-cross suppression assays were performed, T21 Tregs were per-
fectly capable of suppressing D21 CD8+T cells and CD4+Tconv cells.
However, both effector CD8+ T and CD4+ Tconv cells from people
with DS were resistant to Treg-mediated suppression, independent of
Treg karyotype. Resistance to suppression has previously been reported
in different autoimmune diseases such as type I diabetes (63) and SLE
(50). Although the mechanisms leading to effector T cell resistance in
DS are unknown at this point, continued exposure to cytokines that are
elevated in people with DS, such as TNF-α (10), have been shown to
induce T cell resistance to suppression (64). Moreover, both CD8+ and
CD4+ Tconv cells from people with DS show increased proliferation
rates upon stimulation compared to controls while producing higher
levels of effector molecules, which could potentially explain their re-
sistance to Treg-mediated suppression.
Repeatedly, our work points to hyperactive IFN signaling as a
potential driver of the observed dysregulation of T cell homeo-
stasis in DS. RNAseq analysis revealed a positive correlation
between IFN transcriptional scores, CD3/CD28 activation
scores, and expression of T-bet and EOMES (39, 43). Further-
more, GSEA analysis revealed that T cells from adults with DS
have transcriptome signatures indicative of both increased dif-
ferentiation and hyperactivation. The previously observed over-
expression of IFNRs in T cells and other cell types with T21 (9)
and the clear hyperreactivity that diverse T cell subsets show
upon IFN-α stimulation could have profound impacts in shaping
the T cell compartment.
Finally, our results point to inhibition of IFN signaling as a
therapeutic strategy in DS, particularly for the T cell-driven
autoimmune conditions that are more prevalent in this pop-
ulation. IFN signaling can be blocked by a number of strategies,
including inhibitors of JAK kinases which are approved for the
treatment of autoimmune conditions such as rheumatoid ar-
thritis (65). In fact, we recently reported 2 cases of JAK in-
hibition in individuals with DS, with remarkable therapeutic
benefit for alopecia areata, a T cell-driven autoimmune disorder
more prevalent in DS (66). We believe our results justify a
thorough investigation of the potential therapeutic benefits of
anti-IFN strategies in people with DS.
Methods
Study Approval.All donors were enrolled under a study protocol approved by
the Colorado Multiple Institutional Review Board, known as the Crnic Institute’s
Human Trisome Project (COMIRB #15-2170, www.trisome.org). Written informed
consent was obtained from parents or guardians of each participant, and assent
was obtained from participants over the age of 7 y who were cognitively able to
assent. Cohort information can be found in Dataset S2.
Flow Cytometry. Blood samples were processed and stained according to
standard procedures. For more details on antibodies, flow cytometry, and
software, see SI Appendix, Materials and Methods.
In Vitro Assays. In vitro suppression assays were performed according to a
protocol modified from ref. 67. For more details, see SI Appendix, Materials
and Methods.
RNAseq. For RNAseq of WBCs, blood samples were immediately processed
using a previously described protocol (10). For more details, see SI Appendix,
Materials and Methods.
Mass Cytometry Antibody Staining and Data Acquisition. The procedure for
mass cytometry analyses and the antibody−metal conjugates used are de-
tailed in SI Appendix, Materials and Methods.
Meso Scale Discovery Assays (MSD). Cytokines were measured from plasma
samples of 128 individuals (Datasets S2E and S3C) and from supernatant of
in vitro stimulated CD8+ and CD4+ Tconv cells of 20 individuals with anti-
CD3/CD28 (Datasets S2B and S3 A and B) using V-PLEX immunoassays and
a Meso QuickPlex SQ120 from Meso Scale Diagnostics per manufacturer’s
instructions.
Statistical Analysis. All statistical analyses are detailed in SI Appendix, Ma-
terials and Methods.
Data Availability. RNAseq datasets have been deposited in the Gene Ex-
pression Omnibus (GEO) under accession numbers GSE128622 for WBCs (68)
and GSE84531 for T cells (51). All other datasets and code have been de-
posited in the Open Science Framework database and can be accessed at
https://osf.io/rzpyu/ (22) and https://osf.io/p5kfm/ (56).
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